Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 607 results for "Ibrutinib"

FDA grants Breakthrough designation to ibrutinib in cGVHD
European Pharmaceutical Review

Pending EC decision: Imbruvica, ibrutinib, Opinion date: 21-J...

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imbruvica. The marketing authorisation holder for this medicinal product ... European Medicines Agency, 1 day ago
[x]  

18 images for Ibrutinib

CPhI.cn, 2 weeks ago
Targeted Oncology, 1 month ago
Pharmafile, 1 month ago
Cancer Therapy Advisor, 1 month ago
Nasdaq, 1 month ago
Pharmafile, 2 months ago
Cancer Therapy Advisor, 3 months ago
Irish Medical Times, 3 months ago
OncLive, 3 months ago
OncoTherapy Network, 3 months ago

Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD

FDA granted Imbruvica (ibrutinib) Breakthrough Therapy designation and Orphan Drug designation as a monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure or one more lines of systematic therapy. This ...
 PharmTech.com3 weeks ago

EHA 2016: The influence of ibrutinib on ...

Loading........ 76 views Description: Simon Rule, MD from Derriford Hospital, Plymouth, UK outlines his presentation on his work with ibrutinib. Prof Rule discusses the outcome of a compilation of three trials involving the single-agent ...
 Oncology Tube4 weeks ago BRIEF-Janssen to present data from 6 compounds at 2016 ASCO annual meeting  Reuters UK2 months ago Pfizer says will present data on 6 drugs at ASCO meeting  Yahoo! Finance2 months ago Janssen to Present Data from Six Compounds Including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting  WorldNetDaily2 months ago
[x]  

TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib, Recaps Long-Term Safety, Efficacy Data of TGR-1202 in CLL, NHLs

TG Therapeutics, Inc. (NASDAQ: TGTX ) today announced data presented during the 21st Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, ...
 Benzinga.com1 month ago TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Associa  International Business Times1 month ago TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the  International Business Times1 month ago TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress  International Business Times2 months ago
[x]  

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual ...
 CancerConnect.com1 week ago Janssen's IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia  CNBC1 month ago Janssen's IMBRUVICA®?(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia  Bloomberg1 month ago JANSSEN : 's IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia  4 Traders1 month ago
[x]  

AbbVie Gets Europe's Approval For IMBRUVICA For Chronic Lymphocytic Leukemia Treatment

AbbVie (NYSE: ABBV ) revealed Tuesday that the European Commission (EC) has given its approval for its IMBRUVICA (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL). According to the company, the ...
 Benzinga.com1 month ago AbbVie, Janssen's Imbruvica gets European approval to teat CLL  Pharmafile1 month ago AbbVie's Holistic Oncology Strategy May Drive Its Valuation Higher Still  Seeking Alpha1 month ago

ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference

Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the first public presentation of data on ...
 4 Traders4 days ago
[x]  

Inhibitor Treatments: How Do They Work?

Description: How do inhibitors treatments work? CLL expert Dr. Nicole Lamanna explains ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta). Listen as Dr. Lamanna answers the question, What are we inhibiting? and goes on to define ...
 Oncology Tube1 week ago Growth Kinetics May Help Identify Ibrutinib Resistance in CLL Patients  OncoTherapy Network1 month ago Pathophysiology and Treatment Landscape of CLL  American Journal of Managed Care4 days ago Treating CLL with venetoclax  Oncology Tube2 weeks ago
[x]  

KOL Views: Ibrutinib no silver bullet but could be useful addition to armamentarium for graft-versus-host disease, according to leading expert

You attempted to read KOL Views Results , exclusive content for FirstWord Pharma PLUS members. You currently are not registered for any FirstWord Pharma services. To gain instant access to KOL Views Results plus additional enhanced content and ...
 FirstWord Pharma1 week ago KOL Views: FirstWord to host expert call to discuss how ibrutinib may fit into arsenal of therapies for graft-versus-host disease  FirstWord Pharma1 week ago AbbVie Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease  BioSpace3 weeks ago
MedIndia

CLL: Chemotherapy and Ibrutinib based re...

Loading........ 643 views Description: Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in the western world and has a highly variable course. Advances in diagnosis, risk assessment and front-line treatment ...
 Oncology Tube1 month ago Added benefit of idelalisib drug not proven for patients with CLL  News-Medical.Net2 weeks ago Idelalisib in second-line treatment for CLL: Added benefit again not proven  EurekAlert!2 weeks ago Added advantage of idelalisib drug not proven for patients with CLL  HealthMediciNet.com2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less